Mepolizumab and benralizumab mode of action (IMAGE)

Sichuan International Medical Exchange and Promotion Association

Mepolizumab and benralizumab mode of action

Caption

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL-5), a cytokine crucial for developing, differentiating, and surviving eosinophils in bone marrow. In comparison, benralizumab attaches to interleukin-5 receptor alpha (IL-5Rα) present on eosinophil surfaces.

Credit

Hassan Aboul-Ella

Usage Restrictions

Not applicable

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.